StockData
Immunome Inc. logo

Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$16.78−0.40 (-2.33%)

Close on Nov 18, 2026Market cap $1.91BP/E –Yield –

Immunome net income

Net income is the profit left for shareholders after every expense, interest and tax.

Immunome's net income for the twelve months ending Mar 31, 2026 was -$224.59M. For fiscal 2025 it was -$212.39M. The highest annual figure on record is -$10.44M in fiscal 2019.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$212.39M–
FY2024Dec 31, 2024-$292.96M–
FY2023Dec 31, 2023-$106.81M–
FY2022Dec 31, 2022-$36.90M–
FY2021Dec 31, 2021-$24.71M–
FY2020Dec 31, 2020-$17.84M–
FY2019Dec 31, 2019-$10.44M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$53.84M–
Q4 FY2025Dec 31, 2025-$69.90M–
Q3 FY2025Sep 30, 2025-$57.46M–
Q2 FY2025Jun 30, 2025-$43.40M–
Q1 FY2025Mar 31, 2025-$41.64M–
Q4 FY2024Dec 31, 2024-$80.25M–
Q3 FY2024Sep 30, 2024-$47.10M–
Q2 FY2024Jun 30, 2024-$36.12M–
Q1 FY2024Mar 31, 2024-$129.49M–
Q4 FY2023Dec 31, 2023-$92.63M–
Q3 FY2023Sep 30, 2023-$4.35M–
Q2 FY2023Jun 30, 2023-$5.56M–
Q1 FY2023Mar 31, 2023-$4.27M–
Q4 FY2022Dec 31, 2022-$7.79M–
Q3 FY2022Sep 30, 2022-$8.53M–
Q2 FY2022Jun 30, 2022-$8.92M–
Q1 FY2022Mar 31, 2022-$11.65M–
Q4 FY2021Dec 31, 2021-$7.85M–
Q3 FY2021Sep 30, 2021-$7.72M–
Q2 FY2021Jun 30, 2021-$5.24M–
Q1 FY2021Mar 31, 2021-$3.90M–
Q4 FY2020Dec 31, 2020-$4.07M–
Q3 FY2020Sep 30, 2020-$8.38M–
Q2 FY2020Jun 30, 2020-$2.71M–
Q1 FY2020Mar 31, 2020-$2.68M–
Q4 FY2019Dec 31, 2019-$2.92M–
Q3 FY2019Sep 30, 2019-$2.74M–

More Immunome figures

See a number that looks wrong?